0000000000617708

AUTHOR

Paolo Sportoletti

showing 3 related works from this author

First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated wi…

2021

Abstract Introduction: Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is demonstrated to be achievable and recommended for patients (pts) in sustained deep molecular response (sDMR) who can discontinue tyrosine kinase inhibitor (TKI) treatment and maintain responses in ~50% of cases. While the feasibility and safety of TKI cessation have been largely demonstrated, the strategies of TFR optimization are yet to be clarified. Studies (eg. DESTINY) investigating de-escalation, mainly after imatinib, suggested that a stepwise approach may favor TFR outcome. We present the interim results of the phase 2, prospective, multicenter DANTE study (NCT03874858) evaluating de-escalation…

Oncologymedicine.medical_specialtybusiness.industryFirst lineImmunologyMyeloid leukemiaCell BiologyHematologyInterim analysisBiochemistryNilotinibInternal medicinemedicineIn patientbusinessDe-escalationmedicine.drugBlood
researchProduct

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

2021

Not Available

OncologyMalechronic B cell leukemiachronic lymphocytic leukemia; ibrutinib; 4-factor score; prognosis.Datasets as TopicSeverity of Illness Indexchemistry.chemical_compoundPiperidinesRetrospective analysisMulticenter Studies as TopicChronicLeukemiaHematologyMiddle AgedPrognosisLymphocyticProgression-Free SurvivalIbrutinibFemalemedicine.medical_specialtyreal-word studyFactor scoreAntineoplastic AgentsAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival AnalysisRisk AssessmentNOibrutinibInternal medicineSeverity of illnessmedicineHumansProgression-free survivalProtein Kinase InhibitorsSurvival analysisAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelAdenineB-CellReproducibility of ResultsRetrospective cohort studyAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Analysis; Severity of Illness IndexLeukemia Lymphocytic Chronic B-CellSurvival AnalysisSettore MED/15 - MALATTIE DEL SANGUEchemistrybusinesschronic lymphocytic leukaemiaFollow-Up Studies
researchProduct

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

2020

OncologyCancer Researchmedicine.medical_specialtySurvival risk scoreChronic lymphocytic leukemiaTreatment outcomeAntineoplastic Agentsrisk scoreNOchemistry.chemical_compoundrelapsed/refractory chronic lymphocytic leukemiaAntineoplastic Agents ImmunologicalPiperidinesibrutinibInternal medicinemedicineHumansreal-lifeMolecular Targeted TherapyChronicProtein Kinase InhibitorsFramingham Risk ScoreLeukemiachronic lymphocytic leukemia; risk score; prognosisbusiness.industryAdenineB-CellHematologymedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cellprognostic scoreLymphocyticSurvival risk score real-life relapsed/refractory chronic lymphocytic leukemia ibrutinibLeukemiaSettore MED/15 - MALATTIE DEL SANGUEImmunologicalTreatment OutcomeOncologychemistryIbrutinibRelapsed refractorychronic lymphocytic leukemiabusiness
researchProduct